{"id":"lumiracoxib-drug","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disorders"},{"rate":null,"effect":"Cardiovascular events"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a selective COX-2 inhibitor, lumiracoxib blocks the COX-2 enzyme, which is responsible for producing prostaglandins that mediate inflammation, pain, and fever. By selectively targeting COX-2 over COX-1, the drug aims to provide anti-inflammatory and analgesic effects while potentially reducing gastrointestinal toxicity associated with non-selective NSAIDs.","oneSentence":"Lumiracoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce inflammation and pain.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:46.167Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoarthritis"},{"name":"Rheumatoid arthritis"},{"name":"Acute pain"}]},"trialDetails":[{"nctId":"NCT00348491","phase":"PHASE4","title":"Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-02","conditions":"Pain","enrollment":364},{"nctId":"NCT00267176","phase":"PHASE4","title":"Safety and Efficacy of Lumiracoxib in Patients With Osteoarthritis and With Controlled Hypertension","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-11","conditions":"Osteoarthritis, Controlled Hypertension","enrollment":1020},{"nctId":"NCT01481610","phase":"PHASE2","title":"Safety Study of Renal Function in Patients With Chronic Kidney Failure Taking Lumiracoxib or Diclofenac for Arthralgia","status":"TERMINATED","sponsor":"Hospital Central Sur de Pemex","startDate":"2012-01","conditions":"Kidney Failure, Chronic, Arthralgia","enrollment":28},{"nctId":"NCT00154219","phase":"PHASE3","title":"Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"Osteoarthritis, Hip","enrollment":1200},{"nctId":"NCT00145301","phase":"PHASE3","title":"52 Week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability & Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid & Celecoxib 200 mg od in Pts With Primary OA of Hip, Knee, Hand or Spine","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-09","conditions":"Osteoarthritis","enrollment":3036},{"nctId":"NCT00367315","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-09","conditions":"Knee Osteoarthritis","enrollment":1684},{"nctId":"NCT00476034","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-12","conditions":"Osteoarthritis","enrollment":1312},{"nctId":"NCT00267215","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib","status":"COMPLETED","sponsor":"Novartis","startDate":"2000-11","conditions":"Osteoarthritis","enrollment":330},{"nctId":"NCT00475800","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis(OA)","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-01","conditions":"Osteoarthritis","enrollment":833},{"nctId":"NCT00170872","phase":"PHASE3","title":"6 Week Open-label Trial With Lumiracoxib 200mg o.d. in Primary Knee Osteoarthritis or Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"Osteoarthritis, Rheumatoid Arthritis","enrollment":135},{"nctId":"NCT00366938","phase":"PHASE3","title":"Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-09","conditions":"Osteoarthritis, Knee","enrollment":1464},{"nctId":"NCT00637949","phase":"PHASE3","title":"Safety of Lumiracoxib in Patients With Osteoarthritis","status":"COMPLETED","sponsor":"Novartis","startDate":"2000-12","conditions":"Osteoarthritis","enrollment":309},{"nctId":"NCT00333567","phase":"PHASE4","title":"Efficacy and Safety of Lumiracoxib 400 mg in Arthroscopic Knee Surgery","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-08","conditions":"Pain","enrollment":110},{"nctId":"NCT00350155","phase":"PHASE4","title":"Video Capsule Endoscopy to Investigate the Safety and Tolerability of Lumiracoxib in the Small Bowel","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-05","conditions":"Healthy Volunteers","enrollment":150},{"nctId":"NCT00419796","phase":"PHASE4","title":"Effects of Lumiracoxib and Ibuprofen on Blood Pressure and Urinary Eicosanoid Excretion in Osteoarthritis Patients With Controlled Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Osteoarthritis With Controlled Hypertension","enrollment":78},{"nctId":"NCT00170781","phase":"PHASE4","title":"Efficacy and Safety of Lumiracoxib 400 mg Once Daily in Acute Flares of Gout","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-06","conditions":"Acute Gouty Arthritis","enrollment":234},{"nctId":"NCT00170898","phase":"PHASE4","title":"Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-11","conditions":"Musculoskeletal Pain","enrollment":419}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":95,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Lumiracoxib (drug)","genericName":"Lumiracoxib (drug)","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lumiracoxib selectively inhibits cyclooxygenase-2 (COX-2) to reduce inflammation and pain. Used for Osteoarthritis, Rheumatoid arthritis, Acute pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}